Company Overview and News

 
Danakali well-funded to continue execution phase at Colluli Potash Project

2018-04-27 proactiveinvestors.com.au
Danakali Ltd (ASX:DNK) is well-funded to continue the execution phase of the Colluli Potash Project in Eritrea with $16.4 million in cash as at March 31, 2018.

 
Danakali’s advanced potash project is a cut above the rest

2018-04-11 proactiveinvestors.com.au
Danakali Ltd (ASX:DNK) is focused on the development of the world-class Colluli Potash Project in the East African country of Eritrea.

 
Danakali major shareholder increases interest through option exercise

2018-04-10 proactiveinvestors.com.au
Danakli Ltd (ASX:DNK) has had major shareholder, Well Efficient Ltd, increase its holding to 13.33% in the company.

 
Danakali poised to develop the world's largest undeveloped sulphate of potash deposit

2018-03-27 proactiveinvestors.com.au
Danakali Ltd’s (ASX:DNK) Colluli Potash Project in the Danakil Depression region of Eritrea, East Africa, is the world’s largest undeveloped sulphate of potash (SOP) deposit.

1
Parkway Minerals leveraged to growing demand for fertiliser products

2018-03-06 proactiveinvestors.com.au
Parkway Minerals NL (ASX:PWN) has a portfolio of Australian projects aimed at supplying the fertiliser industry and is leveraged to the German potash assets of Davenport Resources (ASX:DAV).

 
Danakali receives support from director, a show of confidence in Colluli Potash Project

2018-02-26 proactiveinvestors.com.au
Danakali Ltd (ASX:DNK) has received support from director Paul Donaldson as it moves towards development of the Colluli Potash Project in Eritrea.

 
Danakali sulphate of potash reserve supports mine life of 200 years at Colluli

2018-02-19 proactiveinvestors.com.au
Danakali Ltd’s (ASX:DNK) updated sulphate of potash ore reserve provides an expected mine life of circa 200 years at proposed production rates at the Colluli Potash Project in Eritrea.

 
Danakali bags $180,000 from early exercise of unlisted options

2018-02-18 proactiveinvestors.com.au
Danakali Ltd (ASX:DNK) has issued 450,000 new shares with a total value of almost $180,000 after the early exercising of unlisted options.

 
Danakali study puts Colluli potash economics ahead of the pack

2018-01-28 proactiveinvestors.com.au
Danakali Ltd (ASX:DNK) has further improved the economics of its tier-1 Colluli Potash Project in Eritrea with a new study delivering industry leading capital intensity and first quartile operating costs.

 
Danakali appoints Danny Goeman as chief executive officer

2017-12-21 proactiveinvestors.com.au
Danakali Ltd (ASX: DNK) has appointed the experienced Danny Goeman as chief executive officer effective immediately.

 
Danakali receives $1 per share valuation from Hannam & Partners

2017-12-12 proactiveinvestors.com.au
Danakali Ltd (ASX:DNK) continues to advance the Tier-1 Colluli Potash Project in Eritrea, and has recently attracted the attention of UK-based merchant bank, Hannam and Partners.

 
Danakali on track for strong finish to 2017 at Eritrean potash project

2017-12-04 proactiveinvestors.com.au
Danakali Ltd (ASX:DNK) is increasing its focus on firming offtake agreements and advancing debt and financing at the Colluli Potash Project in Eritrea.

 
Danakili on track for strong finish to 2017 at Eritrean potash project

2017-12-04 proactiveinvestors.com.au
Danakili Ltd (ASX:DNK) is increasing its focus on firming offtake agreements and advancing debt and financing at the Colluli Potash Project in Eritrea.

 
Danakali lowers its industry-leading capital costs further

2017-11-29 proactiveinvestors.com.au
Danakli Ltd (ASX:DNK) has revealed positive results from its near-complete front end engineering design (FEED) optimisation work for its top-tier Colluli Potash Project in Eritrea.

 
Danakali reveals mining bid costs are well aligned to the DFS estimates

2017-11-27 proactiveinvestors.com.au
Danakali Ltd (ASX:DNK) and 50:50 joint venture partner, the Eritrean National Mining Corporation (ENAMCO), continue to advance the Tier-1 Colluli Potash Project in Eritrea.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...